Avista Therapeutics

What Avista Therapeutics does

Avista Therapeutics is a preclinical biotechnology company based in Pittsburgh, Pennsylvania that develops adeno-associated virus (AAV) gene therapies for rare inherited retinal diseases and central nervous system (CNS) disorders. The company was founded in 2021 as a spin-out of the University of Pittsburgh and the UPMC Vision Institute, and operates around two complementary technology platforms: the ARTEMIS platform, an AI-driven capsid engineering system that combines proprietary protein language models, molecular dynamics simulations, and large non-human primate datasets with single-cell resolution to design novel AAV capsids; and the Innovation platform, which addresses technical barriers including large gene delivery, modular capsid functionalization, and scalable AAV manufacturing. Avista has produced three disclosed capsid candidates: ATX002 and ATX027 (retinal capsids optimized for intravitreal delivery with 14-33x improvements in cell transduction versus clinical-stage comparators) and ATX001 (a brain-directed capsid for neuronal targeting via ICM/ICV injection).

The company's lead clinical-stage candidate is AVST-101, a gene therapy for X-linked retinoschisis (XLRS), with additional preclinical programs targeting PRPF31 mutations and other inherited retinal dystrophies. Avista has established a flagship strategic collaboration with Roche (announced July 2022) for next-generation ocular disease vectors and an AAV development and cGMP manufacturing partnership with Forge Biologics (announced August 2025) to advance manufacturing for clinical-stage programs. The company is privately held and venture-backed, with UPMC Enterprises among its investors. Its go-to-market model is currently a partnership and licensing model rather than direct commercialization: Avista licenses capsids and platforms to pharmaceutical partners while retaining rights to advance its own pipeline candidates.

Avista's commercial profile is that of a preclinical R&D-stage biotech with no marketed products, no disclosed pricing, and no product revenue. Revenue mechanics, to the extent they exist, are based on collaboration milestones, R&D service arrangements, and licensing agreements rather than product sales. The customer base is therefore composed of strategic pharmaceutical partners (Roche, Forge Biologics) and, downstream, patients with inherited retinal and CNS disorders. The company participates in major ophthalmology and gene therapy conferences (ARVO, ASGCT) and pursues scientific publication channels for visibility, with active recruitment of ML scientists, AAV CMC experts, and ophthalmology researchers from institutions including Harvard, Stanford, UC Berkeley, Carnegie Mellon, Johns Hopkins, and the University of Pittsburgh.

Name

Avista Therapeutics

Legal name

Avista Therapeutics

Website

https://avistatx.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Avista Therapeutics is a preclinical Pittsburgh-based biotechnology company developing AI-engineered AAV gene therapies for inherited retinal diseases and CNS disorders, with lead candidate AVST-101 for X-linked retinoschisis and strategic partnerships with Roche and Forge Biologics.

Ownership category

akta.pro rank

Product category

Gene Therapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

AAV Vector Gene Therapy Developers (HLAAACAA)

akta.pro secondary industries

Ophthalmology Gene Therapies (HLAAACAG), Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Rare Ophthalmology Disorder Therapies (HLAIAIAK), Neurology/CNS Gene Therapies (HLAAACAH), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)

Keywords

• AAV gene therapy
• Retinal gene therapy
• Capsid engineering
• AI drug discovery
• Rare ophthalmic diseases

Headquarters

HQ city

Pittsburgh

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Distribution channels1 record

Marketing channels3 records

Core offering

Avista Therapeutics develops AAV-based gene therapies targeting rare inherited retinal diseases and CNS disorders. Its core deliverable is the ARTEMIS AI-driven capsid engineering platform, which designs novel AAV capsids (e.g., ATX002, ATX027, ATX001) optimized for retinal and neuronal delivery, alongside a pipeline of preclinical gene therapy candidates led by AVST-101 for X-linked retinoschisis (XLRS). The company monetizes these assets primarily through vector licensing and co-development partnerships with larger pharmaceutical and biotechnology firms.

Product overview

Avista Therapeutics is a preclinical gene therapy company offering a dual-platform approach: the Artemis AI platform for capsid engineering and the Innovation platform addressing technological barriers. The Artemis platform leverages proprietary protein language models and molecular dynamics to design novel AAV capsids (ATX001, ATX002, ATX027) optimized for retinal and CNS delivery. The Innovation platform focuses on large gene delivery, AAV manufacturing, functionalized capsids, and novel vector development. The company is advancing pipeline candidates including AVST-101 for XLRS, as well as PRPF31 and other retinal disease programs, all in preclinical stages.

Differentiator

Problem solved

Functional benefit

Products and services

• ARTEMIS platform AI-powered capsid engineering platform that integrates high-quality in vivo datasets, proprietary protein language models, and molecular dynamics simulations to generate novel AAV capsids with enhanced targeting and transduction functionality for gene therapy delivery. Sold/licensed to pharmaceutical and biotechnology partners developing gene therapies for retinal and CNS diseases.
• Innovation platform Multi-program technology platform that addresses critical barriers to gene therapy development including large gene delivery beyond traditional AAV packaging limits, AAV manufacturing scalability, modular functionalized capsid decoration for cell-type targeting, and novel vector development beyond AAV. Licensed and made available to gene therapy developers.
• ATX002 capsid AAV capsid engineered by the ARTEMIS platform for retinal gene therapy via intravitreal delivery. Produces strong pan-retinal expression across all regions of the retina including the fovea and periphery, achieving a 14x increase in cells transduced versus clinical-stage 7m8 and a 24x increase versus AAV2. Designed for partners developing retinal gene therapies.
• ATX027 capsid AAV capsid engineered by the ARTEMIS platform for retinal gene therapy via intravitreal delivery. Produces robust pan-retinal expression across all regions of the retina, achieving a 19x increase in cells transduced versus clinical-stage 7m8 and a 33x increase versus AAV2. Designed for partners developing retinal gene therapies.
• ATX001 capsid AAV capsid engineered by the ARTEMIS platform for CNS gene therapy via local delivery. Produces robust distribution throughout the brain from intracerebral (ICM) and intracerebroventricular (ICV) injection, with specific targeting of neurons. Designed for partners developing CNS gene therapies.
• AVST-101 gene therapy candidate Preclinical gene therapy candidate targeting X-linked retinoschisis (XLRS), being developed under a co-development and manufacturing agreement with Forge Biologics to enable AAV development and cGMP production for clinical advancement.

Quantifiable outcome

• 14x increase in cells transduced compared to clinical-stage 7m8 for ATX002 capsid
• +3 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Partnerships

Three partnerships are on record, tiered core and flagship.

• Forge BiologicscoreTechnology or Integration · 13 August 2025Avista Therapeutics and Forge Biologics announced an AAV development and cGMP manufacturing partnership. This collaboration advances AVST-101, a gene therapy candidate for X-linked retinoschisis, and establishes manufacturing capabilities for clinical-stage programs.
• RocheflagshipStrategic or Co-development Partner · 19 July 2022Avista Therapeutics partnered with Roche to develop next-generation AAV gene therapy vectors for ocular diseases. This strategic collaboration leverages Avista's advanced capsid engineering capabilities to create improved vectors for treating eye conditions.
• University of Pittsburgh and UPMC Vision InstitutecoreStrategic or Co-development PartnerAvista Therapeutics was spun out of technology developed at and licensed from the University of Pittsburgh and the UPMC Vision Institute. The company maintains ongoing relationships for continued technology development and licensing.

Recent moves7 records

Expansion highlights6 records

Direct peers

• MeiraGTx: Clinical-stage ocular gene therapy company with multiple inherited retinal disease programs and in-house AAV manufacturing. Direct peer in ocular gene therapy with deeper clinical pipeline.
• Dyno Therapeutics: AI-native AAV capsid engineering company using machine learning to design novel vectors. Has partnerships with Novartis and Roche. Closest direct competitor to Avista's ARTEMIS approach, leveraging high-throughput in vivo data and ML for capsid discovery.
• Beacon Therapeutics: Ocular gene therapy company developing AGTC-501 for XLRS, directly competing with AVST-101. Also addresses inherited retinal diseases using AAV vectors, making it one of Avista's closest clinical-stage competitors.
• Kriya Therapeutics: Engineered AAV-based gene therapy platform with programs in ophthalmology, metabolic disease, and oncology. Has acquired platform technologies (e.g., Warden Bio) and pursues a platform-plus-pipeline model comparable to Avista's ARTEMIS and Innovation platforms.
• Atsena Therapeutics: Clinical-stage AAV gene therapy company developing ATSN-201 for X-linked retinoschisis (XLRS), directly competing with Avista's AVST-101 in the same indication. Uses novel AAV capsids for inherited retinal diseases.
• 4D Molecular Therapeutics: Uses directed evolution to engineer AAV capsids for therapeutic use, with clinical programs in ophthalmology (4D-150 for wet AMD), cardiology, and pulmonology. Direct peer to Avista's ARTEMIS platform approach.
• Adverum Biotechnologies: Clinical-stage AAV gene therapy company with a leading ocular program (ADX-2191/ixoberogene soroparvovec for wet AMD) and a manufacturing platform for AAV. Direct peer in ocular AAV delivery.
• Affinia Therapeutics: AI-enabled AAV capsid engineering company developing gene therapies for CNS and muscular disorders. Direct peer using a comparable technology stack (machine learning + capsid design) to Avista's ARTEMIS.
• Voyager Therapeutics: Clinical-stage gene therapy company with proprietary AAV capsid engineering (TRACER platform) and CNS-focused pipeline. Direct peer with similar platform-plus-pipeline strategy.

Broad incumbents

• REGENXBIO: Established AAV gene therapy platform with multiple clinical-stage ocular and CNS programs (ABBV-RGX-314, RGX-121, RGX-202). Owns foundational AAV IP and competes with Avista's capsid platform while having far greater clinical depth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/AvistaTx

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avista Therapeutics